CIViC Evidence Items
35 evidence items indexed
Evidence Level Distribution
CIViC evidence levels reflect study design quality, from A (strongest) to E (weakest).
AValidated — meta-analysis, systematic review, or major guideline
BClinical — prospective trial or retrospective cohort study
CCase study — single case report or small case series
DPreclinical — in vitro or animal model data
EInferential — computational prediction or biological rationale
Gene × Evidence Type
Count of CIViC evidence items per gene and evidence type category. Hover a column header for the type definition.
| Predictive | Diagnostic | Prognostic | Functional | Predispos. | Oncogenic | |
|---|---|---|---|---|---|---|
| BCR::ABL1 | 323 | 11 | ||||
| BRAF | 186 | 4 | 26 | 2 | 1 | |
| EGFR | 248 | 12 | 3 | 2 | ||
| EML4::ALK | 64 | |||||
| ERBB2 | 142 | 2 | ||||
| FLT3 | 55 | 2 | 21 | |||
| KIT | 102 | 3 | 7 | |||
| KRAS | 159 | 4 | 24 | 4 | ||
| PIK3CA | 156 | 16 | 4 | |||
| PTEN | 53 | 1 | 3 | 1 | 2 | 1 |
| TP53 | 52 | 40 | 100 | 2 | ||
| VHL | 5 | 2 | 3 | 635 | 15 |
Predictive:Links a variant to treatment response or resistance
Diagnostic:Supports or refutes a specific disease diagnosis
Prognostic:Informs disease progression or clinical outcome
Functional:Characterises the biological effect of a variant
Predisposing:Germline variant associated with cancer predisposition
Oncogenic:Characterises the variant's role in oncogenesis
| Level | Gene | Variant | Type | Direction | Significance | Disease | Drugs | Source |
|---|---|---|---|---|---|---|---|---|
| A | NPM1 | EXON 11 MUTATION | Diagnostic | Supports | Positive | Acute Myeloid Leukemia | Vardiman et al., 2009 | |
| B | NPM1 | EXON 11 MUTATION | Prognostic | Supports | Better Outcome | Acute Myeloid Leukemia | Schnittger et al., 2005 | |
| B | NPM1 | EXON 11 MUTATION | Diagnostic | Supports | Negative | Acute Myeloid Leukemia | Schnittger et al., 2005 | |
| B | NPM1 | EXON 11 MUTATION | Diagnostic | Supports | Positive | Acute Myeloid Leukemia | Schnittger et al., 2005 | |
| B | NPM1 | EXON 11 MUTATION | Prognostic | Supports | Better Outcome | Acute Myeloid Leukemia | Gale et al., 2008 | |
| B | NPM1 | EXON 11 MUTATION | Prognostic | Supports | Better Outcome | Acute Myeloid Leukemia | Linch et al., 2014 | |
| B | NPM1 | EXON 11 MUTATION | Prognostic | Supports | Better Outcome | Acute Myeloid Leukemia | Becker et al., 2010 | |
| B | NPM1 | EXON 11 MUTATION | Prognostic | Supports | Poor Outcome | Acute Myeloid Leukemia | Ivey et al., 2016 | |
| B | NPM1 | MUTATION | Diagnostic | Supports | Positive | Acute Myeloid Leukemia With Mutated NPM1 | Falini et al., 2005 | |
| B | NPM1 | MUTATION | Diagnostic | Supports | Positive | Acute Myeloid Leukemia With Mutated NPM1 | Thiede et al., 2006 | |
| B | NPM1 | EXON 11 MUTATION | Diagnostic | Supports | Positive | Acute Myeloid Leukemia | Thiede et al., 2006 | |
| B | NPM1 | EXON 11 MUTATION | Diagnostic | Supports | Positive | Acute Myeloid Leukemia | Schlenk et al., 2009 | |
| B | NPM1 | EXON 11 MUTATION | Predictive | Does Not Support | Sensitivity/Response | Acute Myeloid Leukemia | Tretinoin | Burnett et al., 2010 |
| D | NPM1 | EXON 11 MUTATION | Predictive | Supports | Sensitivity/Response | Acute Myeloid Leukemia | Tretinoin,NSC348884 | Balusu et al., 2011 |
| D | NPM1 | W288FS | Predictive | Supports | Sensitivity/Response | Acute Myeloid Leukemia | NSC348884 | Balusu et al., 2011 |
| E | NPM1 | W288FS | Predictive | Supports | Sensitivity/Response | Acute Myeloid Leukemia | Daunorubicin,Cytarabine,Etoposide | Falini et al., 2005 |
| B | NPM1 | EXON 11 MUTATION | Prognostic | Supports | Better Outcome | Acute Myeloid Leukemia | Schlenk et al., 2009 | |
| B | NPM1 | EXON 11 MUTATION | Prognostic | Supports | Better Outcome | Acute Myeloid Leukemia | Thiede et al., 2006 | |
| B | NPM1 | EXON 11 MUTATION | Prognostic | Supports | Better Outcome | Acute Myeloid Leukemia | Falini et al., 2005 | |
| B | NPM1 | EXON 11 MUTATION | Prognostic | Supports | Better Outcome | Acute Myeloid Leukemia | Büchner et al., 2009 | |
| B | NPM1 | EXON 11 MUTATION | Prognostic | Supports | Better Outcome | Acute Myeloid Leukemia | Gaidzik et al., 2012 | |
| B | NPM1 | EXON 11 MUTATION | Prognostic | Supports | Better Outcome | Acute Myeloid Leukemia | Schlenk et al., 2008 | |
| B | NPM1 | EXON 11 MUTATION | Prognostic | Supports | Better Outcome | Acute Myeloid Leukemia | Döhner et al., 2005 | |
| B | NPM1 | EXON 11 MUTATION | Prognostic | Supports | Poor Outcome | Acute Myeloid Leukemia | Tian et al., 2014 | |
| B | NPM1 | EXON 11 MUTATION | Prognostic | Does Not Support | Better Outcome | Acute Myeloid Leukemia | Boissel et al., 2005 | |
| B | NPM1 | MUTATION | Diagnostic | Supports | Positive | Acute Myeloid Leukemia With Mutated NPM1 | Döhner et al., 2005 | |
| B | NPM1 | W288FS | Prognostic | Does Not Support | Better Outcome | Acute Myeloid Leukemia | Ley et al., 2010 | |
| B | NPM1 | EXON 11 MUTATION | Diagnostic | Supports | Positive | Acute Myeloid Leukemia | Gale et al., 2008 | |
| B | NPM1 | EXON 11 MUTATION | Predictive | Supports | Sensitivity/Response | Acute Myeloid Leukemia | Tretinoin | Schlenk et al., 2009 |
| B | NPM1 | EXON 11 MUTATION | Predictive | Supports | Sensitivity/Response | Acute Myeloid Leukemia | Daunorubicin | Patel et al., 2012 |
| B | NPM1 | EXON 11 MUTATION | Predictive | Supports | Sensitivity/Response | Acute Myeloid Leukemia | Valproic Acid | Tassara et al., 2014 |
| E | NPM1 | EXON 11 MUTATION | Predictive | Supports | Sensitivity/Response | Acute Myeloid Leukemia | Anti-CD123,Anti-CD33 | Ehninger et al., 2014 |
| E | NPM1 | EXON 11 MUTATION | Predictive | Supports | Sensitivity/Response | Acute Myeloid Leukemia | Anti-CD33 | Ehninger et al., 2014 |
| B | NPM1 | EXON 11 MUTATION | Prognostic | Supports | Better Outcome | Acute Myeloid Leukemia | Patel et al., 2012 | |
| B | NPM1 | EXON 11 MUTATION | Prognostic | Supports | Poor Outcome | Acute Myeloid Leukemia | Schnittger et al., 2009 |